##common.pageHeaderLogo.altText##
DOI:
https://doi.org/10.57187/4790

Original article

Vol. 156 No. 4 (2026)

Impact of local treatment on survival outcomes in patients with metastatic lung cancer with oligoprogression undergoing immunotherapy

Cite this as:
Swiss Med Wkly. 2026;156:4790
Published
27.04.2026

Summary

PURPOSE: Immune checkpoint inhibitors have revolutionised the management of non-small cell lung cancer (NSCLC) without oncogenic addictions and have improved its prognosis. A manifestation of acquired resistance to immunotherapy, which is typically seen in a restricted number of lesions and metastatic locations (oligoprogression), has been reported. In cases of oligoprogressive disease, local ablative therapies may represent the main therapeutic approaches, and their significance is further amplified for patients with metastatic NSCLC undergoing immunotherapy.

METHODS: This monocentric retrospective study included 49 patients with metastatic NSCLC treated with immunotherapy, either as a standalone treatment or in combination with chemotherapy. The patients also underwent local ablative therapy in the context of oligoprogression. Clinical and oncological characteristics were assessed, along with overall survival and progression-free survival.

RESULTS: The clinical and oncological characteristics were generally consistent with those expected in the general population of patients with metastatic NSCLC. A median overall survival of 28 months (95% CI: 17.4%–33%), measured from the initiation of local treatment, was reported. The 5-year overall survival rate was 12.36%, and the median progression-free survival was 7.56 months (95% CI: 6.01%–11%). The addition of local ablative therapy to immunotherapy was not associated with increased toxicity.

CONCLUSION: The addition of local ablative therapy in cases of oligoprogression as part of the treatment of metastatic NSCLC treated with immunotherapy alone or in combination with chemotherapy appears to be a therapeutic strategy for slowing disease progression.

References

  1. 1. Debieuvre D, Locher C, Falchero L, Duval Y, Molinier O, Morel H, et al. Vingt ans d’épidémiologie des cancers broncho-pulmonaires diagnostiqués dans les hôpitaux non-universitaires français, l’étude KBP-2020-CPHG comparée aux éditions 2000 et 2010. Rev Malad Respir Actual. 2022 Jan;14(1):24–5. doi: https://doi.org/10.1016/j.rmra.2021.11.038
  2. 2. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al.; KEYNOTE-024 Investigators. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016 Nov;375(19):1823–33. doi: https://doi.org/10.1056/NEJMoa1606774
  3. 3. Tsai CJ, Yang JT, Shaverdian N, Patel J, Shepherd AF, Eng J, et al.; CURB Study Group. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. Lancet. 2024 Jan;403(10422):171–82. doi: https://doi.org/10.1016/S0140-6736(23)01857-3
  4. 4. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995 Jan;13(1):8–10. doi: https://doi.org/10.1200/JCO.1995.13.1.8
  5. 5. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al.; ESMO Guidelines Committee. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct;29 Suppl 4:iv192–237. doi: https://doi.org/10.1093/annonc/mdy275
  6. 6. Franceschini D, De Rose F, Cozzi S, Franzese C, Rossi S, Finocchiaro G, et al. The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: state of the art. Crit Rev Oncol Hematol. 2020 Apr;148:102894. doi: https://doi.org/10.1016/j.critrevonc.2020.102894
  7. 7. Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020 Jan;21(1):e18–28. doi: https://doi.org/10.1016/S1470-2045(19)30718-1
  8. 8. Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol. 2020 Sep;38(25):2830–8. doi: https://doi.org/10.1200/JCO.20.00818
  9. 9. Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019 Jun;37(18):1558–65. doi: https://doi.org/10.1200/JCO.19.00201
  10. 10. Lee HI, Choi EK, Kim SS, Shin YS, Park J, Choi CM, et al. Local Ablative Therapy Combined With Pembrolizumab in Patients With Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Recursive Partitioning Analysis. Int J Radiat Oncol Biol Phys. 2024 Nov;120(3):698–707. doi: https://doi.org/10.1016/j.ijrobp.2024.05.015
  11. 11. Morinaga D, Sakakibara-Konishi J, Kamada R, Kashima M, Tsuji K, Ito S, et al. Frequency and Prognostic Impact of Local Ablation Therapy for Oligoprogression in Non-Small Cell Lung Cancer. Thorac Cancer. 2025 Jul;16(13):e70119. doi: https://doi.org/10.1111/1759-7714.70119
  12. 12. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. J Clin Oncol. 2019 Mar;37(7):537–46. doi: https://doi.org/10.1200/JCO.18.00149
  13. 13. Prelaj A, Pircher CC, Massa G, Martelli V, Corrao G, Lo Russo G, et al. Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression. Cancers (Basel). 2021 Mar;13(6):1300. doi: https://doi.org/10.3390/cancers13061300
  14. 14. Kim C, Hoang CD, Kesarwala AH, Schrump DS, Guha U, Rajan A. Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 Feb;12(2):179–93. doi: https://doi.org/10.1016/j.jtho.2016.10.012
  15. 15. Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012 Mar;366(10):883–92. doi: https://doi.org/10.1056/NEJMoa1113205
  16. 16. Hu F, Xu J, Zhang B, Li C, Nie W, Gu P, et al. Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations. Clin Lung Cancer. 2019 Jan;20(1):e81–90. doi: https://doi.org/10.1016/j.cllc.2018.09.010
  17. 17. Fallet V, Matton L, Schernberg A, Canellas A, Cornelis FH, Cadranel J. Local ablative therapy in oncogenic-driven oligometastatic non-small cell lung cancer: present and ongoing strategies-a narrative review. Transl Lung Cancer Res. 2021 Jul;10(7):3457–72. doi: https://doi.org/10.21037/tlcr-20-1152
  18. 18. Griswold CR, Kerrigan K, Patel SB. Combination of Local Ablative Therapy and Continuation of Immune Checkpoint Inhibitor (ICI) Therapy Provides Durable Treatment Response Past Oligometastatic Progression in NSCLC: A Case Report. Case Rep Oncol. 2019 Nov;12(3):866–71. doi: https://doi.org/10.1159/000504473
  19. 19. Guisier F, Gervais R, Husseini KE, Assié JB, Geier M, Decroisette C, et al. Local ablative treatment and treatment beyond progression for oligo-progression in stage IV non-small cell lung cancer after tumour response to anti-PD1 treatment. Ann Oncol. 2019 Oct;30:v620–1. doi: https://doi.org/10.1093/annonc/mdz260.034